Volume 27, Number 7—July 2021
CME ACTIVITY - Research
Non–C. difficile Clostridioides Bacteremia in Intensive Care Patients, France
Table 3
Characteristic | No. (%) patients |
||||||
---|---|---|---|---|---|---|---|
All patients, n = 135 |
Survived, n = 65 |
Died in ICU, n = 70 |
|||||
Clostridium species | |||||||
Perfringens | 42 (31) | 16 (25) | 26 (37) | ||||
Ramosum | 18 (13) | 10 (15) | 8 (11) | ||||
Any Clostridioides sp. | 16 (12) | 6 (9) | 10 (14) | ||||
Tertium | 14 (10) | 9 (14) | 5 (7) | ||||
Clostridiforme | 12 (9) | 8 (12) | 4 (6) | ||||
Septicum | 10 (7) | 2 (3) | 8 (11) | ||||
Innocuum | 6 (4) | 5 (8) | 1 (1) | ||||
Butyricum | 4 (3) | 2 (3) | 2 (3) | ||||
Paraputrificum | 3 (2) | 2 (3) | 1 (1) | ||||
Baratii | 2 (1) | 1 (2) | 1 (1) | ||||
Orbiscindens | 2 (1) | 1 (2) | 1 (1) | ||||
Sporogenes | 2 (1) | 1 (2) | 1 (1) | ||||
Cadaveris | 1 (1) | 0 (0) | 1 (1) | ||||
Novyi | 1 (1) | 1 (2) | 0 (0) | ||||
Sordellii | 1 (1) | 0 (0) | 1 (1) | ||||
Symbosium |
1 (1) |
1 (2) |
0 (0) |
||||
No. positive blood cultures for Clostridioides spp. | |||||||
1 | 117 (87) | 52 (80) | 65 (93) | ||||
2 | 13 (10) | 9 (14) | 4 (6) | ||||
3 |
5 (4) |
4 (6) |
1 (1) |
||||
Other microbes associated with Clostridioides bacteremia, n = 49 | 27 | 22 | |||||
Gram-negative bacteria | 33 (67) | 20 (74) | 13 (59) | ||||
Gram-positive bacteria | 24 (49) | 12 (44) | 12 (55) | ||||
Candida fungemia |
1 (2) |
1 (4) |
0 (0) |
||||
Effectiveness of tested antimicrobial drugs against Clostridioides species | |||||||
Penicillin, n = 84 | 83 (99) | 37 (100) | 46 (98) | ||||
Clindamycin, n = 67 | 46 (69) | 22 (67) | 24 (71) | ||||
Vancomycin, n = 67 | 67 (100) | 33 (100) | 34 (100) | ||||
Metronidazole, n = 84 |
82 (98) |
36 (97) |
46 (98) |
||||
Patients receiving drugs | 110 (91) | 64 (98) | 46 (82) | ||||
Beta-lactams | 102 (94) | 60 (94) | 42 (95) | ||||
Amoxicillin/clavulanic acid | 9 (9) | 6 (10) | 3 (7) | ||||
Piperacillin/tazobactam | 46 (45) | 25 (42) | 21 (50) | ||||
Cephalosporins | 22 (22) | 15 (25) | 7 (17) | ||||
Carbapenems | 26 (25) | 15 (25) | 11 (26) | ||||
Aminoglycoside | 58 (54) | 34 (53) | 24 (55) | ||||
Anti–gram positive bacteria | 46 (43) | 29 (45) | 17 (39) | ||||
Metronidazole | 39 (36) | 26 (41) | 13 (30) | ||||
Others | 10 (9) | 5 (8) | 5 (11) | ||||
Missing data |
2 |
0 |
2 |
||||
Origin of bacteremia | |||||||
Digestive origin | 87 (74) | 43 (70) | 44 (79) | ||||
Bowel pathology | 33 (28) | 14 (23) | 19 (34) | ||||
Mesenteric ischemia | 25 (21) | 7 (11) | 18 (32) | ||||
Peritonitis | 19 (16) | 16 (26) | 3 (5) | ||||
Pancreatic or biliary origin | 10 (9) | 6 (10) | 4 (7) | ||||
Myonecrosis | 19 (16) | 11 (18) | 8 (14) | ||||
Abscess | 8 (7) | 5 (8) | 3 (5) | ||||
Pneumonia |
3 (3) |
2 (3) |
1 (2) |
||||
Missing data | 18 |
4 |
14 |
Page created: May 27, 2021
Page updated: June 18, 2021
Page reviewed: June 18, 2021
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.